Savara (SVRA) Other financing activities (2010 - 2026)
Savara (SVRA) reported Other financing activities of $240000.0 for Q1 2026, up 11.63% year-over-year from $215000.0 in Q1 2025, and down 94.99% on a QoQ basis from $4.8 million in Q4 2025.
Savara (SVRA) has 13 years of Other financing activities data on file, last reported at $240000.0 in Q1 2026.
- Quarterly Other financing activities rose 11.63% year-over-year to $240000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.2 million (up 327.57% YoY) and the FY2025 annual result came in at $5.1 million, up 416.58% from the prior year.
- Other financing activities eased to $240000.0 in Q1 2026 per SVRA's latest filing, from $4.8 million in the prior quarter.
- Across five years, Other financing activities topped out at $4.8 million in Q4 2025 and bottomed at $1000.0 in Q1 2022.
- The 5-year median for Other financing activities is $94000.0 (2024), against an average of $504615.4.
- The widest annual swing landed in 2023, when Other financing activities jumped 18100.0%; it then sank 75.53% in 2025.
- Tracing SVRA's Other financing activities over 5 years: stood at $1000.0 in 2022, then jumped by 18100.0% to $182000.0 in 2023, then jumped by 392.86% to $897000.0 in 2024, then soared by 433.67% to $4.8 million in 2025, then sank by 94.99% to $240000.0 in 2026.
- Per Business Quant, the three latest SVRA Other financing activities figures stand at $240000.0 (Q1 2026), $4.8 million (Q4 2025), and $23000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Savara | 1.30 Bn | 1.30 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 240,000.00 |
| Mar 31, 2026 | 240,000.00 |
| Dec 31, 2025 | 4.79 Mn |
| Dec 31, 2025 | 4.79 Mn |
| Sep 30, 2025 | 23,000.00 |
| Sep 30, 2025 | 23,000.00 |
| Jun 30, 2025 | 115,000.00 |
| Jun 30, 2025 | 115,000.00 |
| Mar 31, 2025 | 215,000.00 |
| Mar 31, 2025 | 215,000.00 |
| Dec 31, 2024 | 897,000.00 |
| Dec 31, 2024 | 897,000.00 |
| Sep 30, 2024 | 94,000.00 |
| Sep 30, 2024 | 94,000.00 |
| Jun 30, 2024 | 2,000.00 |
| Jun 30, 2024 | 2,000.00 |
| Mar 31, 2024 | 2,000.00 |
| Mar 31, 2024 | 2,000.00 |
| Sep 30, 2023 | 182,000.00 |
| Sep 30, 2023 | 182,000.00 |
| Mar 31, 2023 | 1,000.00 |
| Mar 31, 2023 | 1,000.00 |
| Sep 30, 2022 | 1,000.00 |
| Sep 30, 2022 | 1,000.00 |
| Mar 31, 2022 | 1,000.00 |
| Mar 31, 2022 | 1,000.00 |
| Mar 31, 2017 | 50,000.00 |
| Mar 31, 2017 | 50,000.00 |
| Dec 31, 2016 | 56,000.00 |
| Dec 31, 2016 | 56,000.00 |
| Sep 30, 2016 | 986,000.00 |
| Sep 30, 2016 | 986,000.00 |
| Jun 30, 2016 | -554,000.00 |
| Jun 30, 2016 | -554,000.00 |
| Mar 31, 2016 | 601,000.00 |
| Mar 31, 2016 | 601,000.00 |
| Dec 31, 2015 | -18,000.00 |
| Dec 31, 2015 | -18,000.00 |
| Sep 30, 2015 | 51,000.00 |
| Sep 30, 2015 | 51,000.00 |
| Jun 30, 2015 | 96,000.00 |
| Jun 30, 2015 | 96,000.00 |
| Mar 31, 2015 | 13,000.00 |
| Mar 31, 2015 | 13,000.00 |
| Dec 31, 2014 | 1.34 Mn |
| Dec 31, 2014 | 1.34 Mn |
| Sep 30, 2014 | 122,000.00 |
| Sep 30, 2014 | 122,000.00 |
| Jun 30, 2014 | 279,000.00 |
| Jun 30, 2014 | 279,000.00 |
| Mar 31, 2014 | 316,000.00 |
| Mar 31, 2014 | 316,000.00 |
| Dec 31, 2013 | 116,789.00 |
| Dec 31, 2013 | 116,789.00 |
| Sep 30, 2013 | 242,612.00 |
| Sep 30, 2013 | 242,612.00 |
| Jun 30, 2012 | 3,170.00 |
| Jun 30, 2012 | 3,170.00 |
| Mar 31, 2012 | 47,742.00 |
| Mar 31, 2012 | 47,742.00 |
| Dec 31, 2011 | 1.36 Mn |
| Dec 31, 2011 | 1.36 Mn |
| Mar 31, 2011 | 1.55 Mn |
| Mar 31, 2011 | 1.55 Mn |
| Dec 31, 2010 | 2.00 |
| Dec 31, 2010 | 2.00 |